Table 3: Characteristics of certain HDACIs tested in CTCL.

HDAC class specificityPotencyRoute of administrationClinical StatusStructure

VorinostatI, II, IVnMOralFDA approved (2006)290685.table.003a
HydroxamateBelinostat
(PXD101)
I, II, IVnMOral/intravenousPhase I, II 290685.table.003b
Panobinostat
(LBH589)
I, II, IVnMOralPhase II, III290685.table.003c

BenzamideEntinostat
(MS-275)
I MOralPhase II290685.table.003d

Cyclic tetrapeptideDepsipeptide
(FK228, romidepsin)
I, II, IVnMIntravenousFDA approved (2009)290685.table.003e